Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results
By Adriano Marchese
Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment.
Shares rose 14.6% in ahead of the morning bell to $144.
The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA.
The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint.
Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug.
After that, the company will also share the data with regulators in other countries, it said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
May 04, 2026 07:45 ET (11:45 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States